“clinical-trials” Archives

in
Entry Author Date Location
Often Advocates Of Faster FDA, Patient Groups Wary Of Trump Deregulation 02/10/17 National
Acorda Touts Success in Parkinson’s Drug Study, Awaits Safety Data 02/09/17 New York
No Details Yet, But Amgen Touts Success in Big Heart Drug Study 02/02/17 San Francisco
Tarveda Nabs $30M More as Versant Helps Fund Cancer Drug Push 02/02/17 Boston
Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths 02/01/17 Boston
Investors Sour on Data Debut For Dimension’s Hemophilia Gene Therapy 01/31/17 Boston
Seres Dissects Failed Microbiome Drug Trial, Suggests Changes to FDA 01/31/17 Boston
FibroGen Pushes Forward With Anemia Pill in China, But Big Test Awaits 01/30/17 San Francisco
Novan Acne Drug Hits Targets in One Late-Stage Trial, Fails Another 01/27/17 Raleigh Durham
Jounce Gets $102M As Biotech IPOs Gain Steam in ’17 01/27/17 Boston
Mallinckrodt Filing Pegs Stratatech Deal at $76M, Could Reach $197M 01/26/17 Wisconsin
AnaptysBio Adds More Shares, Raises $75M in Stock Market Debut 01/26/17 San Diego
Cellectar Awarded Another Cancer Drug Patent 01/26/17 Wisconsin
Just Four Months After Series A, Delinia Sells to Celgene For $300M 01/26/17 Boston
Purdue’s On Target Laboratories Lights Up the Fight Against Cancer 01/25/17 Indiana
Ex-FDA Commish Califf Gives Props to Patient Groups—With Caveats 01/23/17 National
Hunting For Pharma Deals, Ovid Bags Epilepsy Drug from Takeda 01/18/17 New York
Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay 01/13/17 National
CEO Kaye Details Insurance Battle As Sarepta Launches Duchenne Drug 01/10/17 Boston
Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug 01/06/17 National
RaNA Expands, Joins Messenger RNA Drug Race With Shire Deal 01/04/17 Boston
Inotek’s Glaucoma Drug Flunks in First Phase 3 Test, Shares Crumble 01/03/17 Boston
First Trial Underway, Jounce Preps IPO To Fund Immuno-Oncology Work 01/03/17 Boston
Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug 12/28/16 Boston
Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More 12/23/16 National
14 for ’17: Key Clinical Data To Watch For Next Year (Part 2) 12/22/16 National
14 For ’17: Key Clinical Data to Watch For Next Year (Part 1) 12/21/16 National
Akebia Gets $265M From Otsuka to Bankroll Anemia Drug Push 12/20/16 Boston
Another Notch For “PARP” Blockers As FDA Approves Clovis Cancer Drug 12/19/16 Boulder/Denver
After Setback, Ophthotech Restructures, Dials Down Eye Drug Studies 12/16/16 New York
Page 2 of 22 « previous page · next page »